Targeting Moderate to Severe Psoriasis: Novel Treatments on the Horizon

Patients with psoriasis (PsO) experience disruptions to their daily functioning due to their condition, with higher disease severity associated with reduced quality of life. The approval of novel therapies over the past several years has greatly expanded the armamentarium for difficult to manage PsO and several agents are in the research pipeline for FDA review. Among these options, small molecule agents targeting new pathways are showing promise in enhancing PsO care, including Janus kinase inhibitors and a recently approved tyrosine kinase 2 (TYK2) inhibitor. Tune into this on-demand webcast to learn about new and emerging therapies for moderate to severe psoriasis featuring leading dermatology experts.

Share

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE).

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb